Describing the progression from Chlamydia trachomatis and Neisseria gonorrhoeae to pelvic inflammatory disease: Systematic review of mathematical modeling studies

Sexually Transmitted Diseases

Volumn 39, Issue 8, 2012, Pages 628-637

  Herzog, Sereina A ^a   Heijne, Janneke C M ^a   Althaus, Christian L ^a   Low, Nicola ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHLAMYDIASIS; COMPARTMENT MODEL; DATA BASE; DISEASE COURSE; GONORRHEA; HUMAN; INDIVIDUAL BASED POPULATION MODEL; MATHEMATICAL MODEL; PELVIC INFLAMMATORY DISEASE; PROBABILITY; PUBLICATION; SYSTEMATIC REVIEW;

CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; FEMALE; GONORRHEA; HUMANS; MODELS, THEORETICAL; NEISSERIA GONORRHOEAE; PELVIC INFLAMMATORY DISEASE; PHYSICAL EXAMINATION; RISK FACTORS;

EID: 84863787610     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31825159ff     Document Type: Article

References (70)

1. Paavonen J, Westrom L, Eschenbach D. Pelvic inflammatory disease. In: Holmes KK, Sparling PF, Stamm W, et al, eds. Sexually Transmitted Diseases. 4th ed. New York, NY: McGraw-Hill Medical, 2008:1017-1050.
2. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2009. Atlanta, GA; CDC, 2010.
3. Westrom L, Joesoef R, Reynolds G, et al. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992; 19:185-192.
4. Oriel JD. The Scars of Venus: A History of Venereology. London, United Kingdom: Springer, 1994.
5. Brunham RC, Garnett GP, Swinton J, et al. Gonococcal infection and human fertility in sub-Saharan Africa. Proc Royal Soc B 1991; 246:173-177.
6. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR Recomm Rep 2010; 59:1-110.
7. Department of Health. Chlamydia screening programme roll out core requirements. London, United Kingdom, 2003. Available at: http://www. chlamydiascreening.nhs.uk/ps/what-is/aims.html. Accessed March 21, 2012.
8. Althaus CL, Heijne JC, Roellin A, et al. Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes. Epidemics 2010; 2:123-131.
9. Smith KJ, Cook RL, Roberts MS. Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: Influence on the cost-effectiveness of different screening intervals. Value Health 2007; 10:358-366. (Pubitemid 47481107)
10. Gottlieb SL, Berman SM, Low N. Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection: How much do we know? J Infect Dis 2010; 201:S156-S167.
11. Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996; 334:1362-1366. (Pubitemid 26152715)
12. Ostergaard L, Andersen B, Møller JK, et al. Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: A cluster-randomized 1-year follow-up study. Clin Infect Dis 2000; 31:951-957. (Pubitemid 32299353)
13. Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: The POPI (prevention of pelvic infection) trial. BMJ 2010; 340:c1642.
14. Garnett GP, Cousens S, Hallett TB, et al. Mathematical models in the evaluation of health programmes. Lancet 2011; 378:515-525.
15. Deleted in proof.
16. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993; 13:322-338. (Pubitemid 24013155)
17. Anderson RM, May RM. Infectious diseases of humans. Oxford, United Kingdom: Oxford University Press, 1992.
18. Keeling MJ, Rohani P. Modeling infectious diseases in humans and animals. Princeton, NJ: Princeton University Press, 2008.
19. Mishra S, Fisman DN, Boily M, et al. The ABC of terms used in mathematical models of infectious diseases. J Epidemiol Community Health 2011; 65:87-94.
20. Halloran ME, Lipsitch M. Infectious disease modeling contributions to the American Journal of Epidemiology. Am J Epidemiol 2005; 161:997-998. (Pubitemid 40734347)
21. Adams EJ, Turner KM, Edmunds WJ, et al. The cost effectiveness of opportunistic chlamydia screening in England. Sex Transm Infect 2007; 83:267-275.
22. Aledort JE, Hook EW, Weinstein MC, et al. The cost effectiveness of gonorrhea screening in urban emergency departments. Sex Transm Dis 2005; 32:425-436. (Pubitemid 40875379)
23. Andersen B, Gundgaard J, Kretzschmar M, et al. Prediction of costs, effectiveness, and disease control of a population-based program using home sampling for diagnosis of urogenital Chlamydia trachomatis infections. Sex Transm Dis 2006; 33:407-415. (Pubitemid 43964749)
24. Blake DR, Gaydos CA, Quinn TC. Cost-effectiveness analysis of screening adolescent males for Chlamydia on admission to detention. Sex Transm Dis 2004; 31:85-95. (Pubitemid 38141641)
25. Buhaug H, Skjeldestad FE, Backe B, et al. Cost effectiveness of testing for chlamydial infections in asymptomatic women. Med Care 1989; 27:833-841.
26. Buhaug H, Skjeldestad FE, Halvorsen LE, et al. Should asymptomatic patients be tested for Chlamydia trachomatis in general practice? Br J Gen Pract 1990; 40:142-145.
27. de Vries R, van Bergen JEAM, de Jong-van den Berg LTW, et al. Systematic screening for Chlamydia trachomatis: Estimating cost-effectiveness using dynamic modeling and Dutch data. Value Health 2006; 9:1-11.
28. Deogan CL, Hansson Bocangel MK, Wamala SP, et al. A cost-effectiveness analysis of the Chlamydia Monday - a community-based intervention to decrease the prevalence of chlamydia in Sweden. Scand J Public Health 2010; 38:141-150.
29. Estany A, Todd M, Vasquez M, et al. Early detection of genital chlamydial infection in women: An economic evaluation. Sex Transm Dis 1989; 16:21-27. (Pubitemid 19096868)
30. Gift T, Walsh C, Haddix A, et al. A cost-effectiveness evaluation of testing and treatment of Chlamydia trachomatis infection among asymptomatic women infected with Neisseria gonorrhoeae. Sex Transm Dis 2002; 29:542-551. (Pubitemid 35001345)
31. Gift TL, Gaydos CA, Kent CK, et al. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women. Sex Transm Dis 2008; 35:S66-S75.
32. Ginocchio RH, Veenstra DL, Connell FA, et al. The clinical and economic consequences of screening young men for genital chlamydial infection. Sex Transm Dis 2003; 30:99-106. (Pubitemid 36184354)
33. Goeree R, Jang D, Blackhouse G, et al. Cost-effectiveness of screening swab or urine specimens for Chlamydia trachomatis from young Canadian women in Ontario. Sex Transm Dis 2001; 28:701-709. (Pubitemid 33130067)
34. Gray RT, Beagley KW, Timms P, et al. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis 2009; 199:1680-1688.
35. Haddix AC, Hillis SD, Kassler WJ. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis 1995; 22:274-280.
36. Howell MR, Kassler WJ, Haddix A. Partner notification to prevent pelvic inflammatory disease in women. Cost-effectiveness of two strategies. Sex Transm Dis 1997; 24:287-292. (Pubitemid 27208981)
37. Howell MR, Quinn TC, Brathwaite W, et al. Screening women for Chlamydia trachomatis in family planning clinics: The cost-effectiveness of DNA amplification assays. Sex Transm Dis 1998; 25:108-117. (Pubitemid 28078370)
38. Hu D, Hook EW, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29 years of age: A cost-effectiveness analysis. Ann Intern Med 2004; 141:501-513.
39. Hu D, Hook EW, Goldie SJ. The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies. Sex Transm Dis 2006; 33:428-436. (Pubitemid 43964752)
40. Kraut-Becher JR, Gift TL, Haddix AC, et al. Cost-effectiveness of universal screening for chlamydia and gonorrhea in US jails. J Urban Health 2004; 81:453-471. (Pubitemid 39128281)
41. Low N, McCarthy A, Macleod J, et al. Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess 2007; 11:1-184.
42. Magid D, Douglas JM, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: An incremental cost-effectiveness analysis. Ann Intern Med 1996; 124:389-399. (Pubitemid 26065070)
43. Mehta SD, Bishai D, Howell MR, et al. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. Sex Transm Dis 2002; 29:83-91. (Pubitemid 34163704)
44. Mrus JM, Biro FM, Huang B, et al. Evaluating adolescents in juvenile detention facilities for urogenital chlamydial infection: Costs and effectiveness of alternative interventions. Arch Pediatr Adolesc Med 2003; 157:696-702. (Pubitemid 36818652)
45. Nettleman MD, Jones RB. Proportional payment for pelvic inflammatory disease: Who should pay for chlamydial screening? Sex Transm Dis 1989; 16:36-40. (Pubitemid 19096871)
46. Nevin RL, Shuping EE, Frick KD, et al. Cost and effectiveness of Chlamydia screening among male military recruits: Markov modeling of complications averted through notification of prior female partners. Sex Transm Dis 2008; 35:705-713.
47. Nuovo J, Melnikow J, Paliescheskey M, et al. Cost-effectiveness analysis of five different antibiotic regimens for the treatment of uncomplicated Chlamydia trachomatis cervicitis. J Am Board Fam Pract 1995; 8:7-16.
48. Nyári T, Nyári C, Woodward M, et al. Screening for Chlamydia trachomatis in asymptomatic women in Hungary. An epidemiological and cost-effectiveness analysis. Acta Obstet Gynecol Scand 2001; 80:300-306. (Pubitemid 32260677)
49. Paavonen J, Puolakkainen M, Paukku M, et al. Cost-benefit analysis of first-void urine Chlamydia trachomatis screening program. Obstet Gynecol 1998; 92:292-298. (Pubitemid 28350866)
50. Petitta A, Hart SM, Bailey EM. Economic evaluation of three methods of treating urogenital chlamydial infections in the emergency department. Pharmacotherapy 1999; 19:648-654. (Pubitemid 29211811)
51. Phillips RS, Aronson MD, Taylor WC, et al. Should tests for Chlamydia trachomatis cervical infection be done during routine gynecologic visits? An analysis of the costs of alternative strategies. Ann Intern Med 1987; 107:188-194. (Pubitemid 17137854)
52. Postma MJ, Welte R, van den Hoek JA, et al. Opportunistische screening op genitale infecties met Chlamydia trachomatis onder de seksueel actieve bevolking in Amsterdam. II. Kosteneffectiviteitsanalyse van screening bij vrouwen. Ned Tijdschr Geneeskd 1999; 143:677-681. (Pubitemid 29157031)
53. Postma M, Welte R, van den Hoek A, et al. Cost-effectiveness of screening asymptomatic women for Chlamydia trachomatis. HEPAC 2000; 1:103-110.
54. Postma MJ, Welte R, van den Hoek JA, et al. Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis. Value Health 2001; 4:266-275. (Pubitemid 32661270)
55. Postma MJ, Welte R, Morré SA. Cost-effectiveness of widespread screening for Chlamydia trachomatis. Expert Opin Pharmacother 2002; 3:1443-1450. (Pubitemid 35174876)
56. Roberts TE, Robinson S, Barton PM, et al. Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK: Economic evaluation of chlamydia screening studies (ClaSS) project. BMJ 2007; 335:291-294. (Pubitemid 47280805)
57. Townshend JR, Turner HS. Analysing the effectiveness of Chlamydia screening. J Oper Res Soc 2000; 51:812-824.
58. Trachtenberg AI, Washington AE, Halldorson S. A cost-based decision analysis for Chlamydia screening in California family planning clinics. Obstet Gynecol 1988; 71:101-108. (Pubitemid 18025087)
59. van Valkengoed IG, Postma MJ, Morré SA, et al. Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. Sex Transm Infect 2001; 77:276-282. (Pubitemid 32682143)
60. Walleser S, Salkeld G, Donovan B. The cost effectiveness of screening for genital Chlamydia trachomatis infection in Australia. Sex Health 2006; 3:225-234.
61. Ward B, Rodger AJ, Jackson TJ. Modelling the impact of opportunistic screening on the sequelae and public healthcare costs of infection with Chlamydia trachomatis in Australian women. Public Health 2006; 120:42-49. (Pubitemid 43013045)
62. Washington AE, Browner WS, Korenbrot CC. Cost-effectiveness of combined treatment for endocervical gonorrhea. Considering co-infection with Chlamydia trachomatis. JAMA 1987; 257: 2056-2060. (Pubitemid 17056747)
63. Welte R, Kretzschmar M, Leidl R, et al. Cost-effectiveness of screening programs for Chlamydia trachomatis: A population-based dynamic approach. Sex Transm Dis 2000; 27:518-529.
64. Welte R, Jager H, Postma MJ. Cost-effectiveness of screening for genital Chlamydia trachomatis. Expert Rev Pharmacoecon Outcomes Res 2001; 1:145-156. (Pubitemid 34649756)
65. Low N, Egger M, Sterne JA, et al. Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: The Uppsala Women's Cohort Study. Sex Transm Infect 2006; 82:212-218. (Pubitemid 43901588)
66. Roberts TE, Robinson S, Barton P, et al. Screening for Chlamydia trachomatis: A systematic review of the economic evaluations and modelling. Sex Transm Infect 2006; 82:193-200. (Pubitemid 43901584)
67. Pal S, Hui W, Peterson EM, et al. Factors influencing the induction of infertility in a mouse model of Chlamydia trachomatis ascending genital tract infection. J Med Microbiol 1998; 47:599-605. (Pubitemid 28313948)
68. Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis 2010; 201:114-125.
69. Aghaizu A, Atherton H, Mallinson H, et al. Incidence of pelvic inflammatory disease in untreated women infected with Chlamydia trachomatis. Int J STD AIDS 2008; 19:283. (Pubitemid 351738783)
70. Blanchard JF, Aral SO. Program Science: An initiative to improve the planning, implementation and evaluation of HIV/sexually transmitted infection prevention programmes. Sex Transm Infect 2011; 87:2-3.